Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published ...

Results of a large clinical trial demonstrated the benefits of an investigational, once-a-day pill called brenso­catib as a ...

With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe ...

A new meta-analysis shows point-of-care testing reduces unnecessary antibiotics in patients experiencing COPD exacerbations, ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis has demonstrated benefits of an investigational, once-a-day pill called brenso catib as ...

Itepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis; phase 3 readouts in COPD ... show that the primary endpoint of annualized exacerbation rate at week 48 was not met ...

The following is a summary of “Bronchiectasis In Patients With Inflammatory Bowel Diseases – Prevalence, Predictors, And Clinical Characteristics,” published in the March 2025 issue of CHEST Journal ...

Sputum specialized proresolving mediators (SPMs), particularly resolvin D1 (RvD1), showed dynamic temporal changes and aided recovery during bacterial acute exacerbations of chronic obstructive ...

Asthma with recurring exacerbations (AREs) is a more severe form of childhood asthma linked to worsened health, high medical costs, and significant challenges for both the patient and their family ...

RCTs including patients with stable and chronic HF without acute exacerbation requiring unplanned hospitalization were not included. No minimum sample size was required for inclusion. The full texts ...

Background: Acute exacerbation of chronic obstructive pulmonary disease ... Exclusion criteria: (1) patients with other lung diseases such as bronchial asthma, bronchiectasis, and lung cancer; (2) ...